Pluristem Therapeutc (PSTI) 1.48 $PSTI
Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
GlobeNewswire - Mon May 16, 2:00AM CDT
-- Trial expands to randomize 20 more patients to receive two injections per patient
PSTI: 1.48 (-0.04)
Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Tue May 10, 5:44AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its fiscal third quarter ended March 31, 2016, and provided clinical and corporate updates.
PSTI: 1.48 (-0.04)
Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke
GlobeNewswire - Thu Apr 21, 3:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company's IP coverage. This license follows Pluristem's recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods.
PSTI: 1.48 (-0.04)
Intermittent Claudication - Pipeline Review, H1 2016 Featuring ID Pharma, Kowa Company, Nuo Therapeutics & Pluristem Therapeutics - Research and Markets
BusinessWire - Wed Mar 23, 1:31PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcbxlb/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H1 2016" report to their offering.
PSTI: 1.48 (-0.04)
Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Wed Feb 10, 6:59AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its second quarter ended December 31, 2015, and provided clinical and corporate updates.
PSTI: 1.48 (-0.04)
Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:07PM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3 Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Communications. Other panel members will include Adi Mohanty, Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick, MD, CEO, Cytori Therapeutics.
PSTI: 1.48 (-0.04), STEM: 0.42 (-0.01)
Pluristem's Placental Cells Prove Superior in Pre-Eclampsia a Leading Cause of Maternal and Fetal Death
ACCESSWIRE - Wed Feb 03, 8:00AM CST
FDA's Coveted Orphan Drug Designation Was Recently given to Pluristem in Pre-Eclampsia; Key Opinion Leader Dr. Brett Mitchell Comments on Clinical Results and Pluristem's Superiority
PSTI: 1.48 (-0.04)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.48 (-0.04), GSK: 40.93 (-1.13), CLBS: 0.53 (unch), MESO: 7.07 (+0.16), ATHX: 2.38 (+0.03), BXLT: 46.02 (-0.18)
Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs
ACCESSWIRE - Thu Jan 28, 11:11AM CST
LAS VEGAS, NV / ACCESSWIRE / January 28, 2016 / Now that investors have gotten their first taste of the potential returns from the treatment of liver diseases, such as hepatitis C, which generated over $12.5 billion in 2014 sales and another $14.3 billion in the first nine months of 2015 for Gilead, companies are now looking to target other large liver disease markets.
INO: 10.62 (-0.39), PSTI: 1.48 (-0.04), GERN: 2.77 (-0.04), STEM: 0.42 (-0.01)
Pluristem to Commence Go-To-Market Pivotal Trial in 2016 for $12 Billion Critical Limb Ischemia Opportunity
ACCESSWIRE - Wed Jan 20, 10:02AM CST
Injection of PLX-PAD cell therapy to eliminate need for endovascular surgery
PSTI: 1.48 (-0.04)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.43 (-0.07), PSTI: 1.48 (-0.04), ATHX: 2.38 (+0.03), CLBS: 0.53 (unch)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 7.07 (+0.16), PSTI: 1.48 (-0.04), CGEN: 6.43 (-0.19), CBLI: 2.61 (+0.01)
Pluristem (PSTI) Gets FDA Approval for Phase I PLX-R18 Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 2:35PM CST
Pluristem Therapeutics (PSTI) announced that the FDA has cleared its IND application to begin a phase I trial on PLX-R18 cells for treating incomplete hematopoietic recovery following hematopoietic cell transplantation.
GILD: 84.45 (-1.32), PSTI: 1.48 (-0.04), AZN: 27.97 (-0.99), ANIK: 49.16 (+0.24)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.48 (-0.04), GALT: 1.42 (-0.05), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08), GLPG: 55.29 (-1.59), GILD: 84.45 (-1.32), IBIO: 0.61 (-0.02), TEVA: 53.01 (-0.30), FGEN: 17.59 (-0.80), CELGZ: 1.46 (-0.04)
MannKind Plunges on Termination of Afrezza Deal with Sanofi
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 1:45PM CST
Shares of MannKind Corporation (MNKD) plummeted 48.4% after the company announced the termination of its license and collaboration agreement with Sanofi (SNY) for Afrezza.
PSTI: 1.48 (-0.04), JUNO: 42.98 (-2.55), SNY: 39.41 (-1.45), MNKD: 1.01 (-0.02)
Pluristem's PLX-PAD Cells Get Orphan Drug Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jan 04, 8:30AM CST
Pluristem Therapeutics announced that the FDA has granted its placental-derived (PLX-PAD) cells Orphan Drug designation for the treatment of severe preeclampsia.
PSTI: 1.48 (-0.04), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), BXLT: 46.02 (-0.18)
Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
GlobeNewswire - Mon May 16, 2:00AM CDT
-- Trial expands to randomize 20 more patients to receive two injections per patient
PSTI: 1.48 (-0.04)
Pluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Tue May 10, 5:44AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its fiscal third quarter ended March 31, 2016, and provided clinical and corporate updates. PSTI: 1.48 (-0.04)
Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke
GlobeNewswire - Thu Apr 21, 3:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company's IP coverage. This license follows Pluristem's recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods. PSTI: 1.48 (-0.04)
Intermittent Claudication - Pipeline Review, H1 2016 Featuring ID Pharma, Kowa Company, Nuo Therapeutics & Pluristem Therapeutics - Research and Markets
BusinessWire - Wed Mar 23, 1:31PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcbxlb/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H1 2016" report to their offering.
PSTI: 1.48 (-0.04)
Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
GlobeNewswire - Wed Feb 10, 6:59AM CST
Pluristem Therapeutics Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its second quarter ended December 31, 2015, and provided clinical and corporate updates. PSTI: 1.48 (-0.04)
Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:07PM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3 Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Communications. Other panel members will include Adi Mohanty, Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick, MD, CEO, Cytori Therapeutics.
PSTI: 1.48 (-0.04), STEM: 0.42 (-0.01)
Pluristem's Placental Cells Prove Superior in Pre-Eclampsia a Leading Cause of Maternal and Fetal Death
ACCESSWIRE - Wed Feb 03, 8:00AM CST
FDA's Coveted Orphan Drug Designation Was Recently given to Pluristem in Pre-Eclampsia; Key Opinion Leader Dr. Brett Mitchell Comments on Clinical Results and Pluristem's Superiority
PSTI: 1.48 (-0.04)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.48 (-0.04), GSK: 40.93 (-1.13), CLBS: 0.53 (unch), MESO: 7.07 (+0.16), ATHX: 2.38 (+0.03), BXLT: 46.02 (-0.18)
Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs
ACCESSWIRE - Thu Jan 28, 11:11AM CST
LAS VEGAS, NV / ACCESSWIRE / January 28, 2016 / Now that investors have gotten their first taste of the potential returns from the treatment of liver diseases, such as hepatitis C, which generated over $12.5 billion in 2014 sales and another $14.3 billion in the first nine months of 2015 for Gilead, companies are now looking to target other large liver disease markets.
INO: 10.62 (-0.39), PSTI: 1.48 (-0.04), GERN: 2.77 (-0.04), STEM: 0.42 (-0.01)
Pluristem to Commence Go-To-Market Pivotal Trial in 2016 for $12 Billion Critical Limb Ischemia Opportunity
ACCESSWIRE - Wed Jan 20, 10:02AM CST
Injection of PLX-PAD cell therapy to eliminate need for endovascular surgery
PSTI: 1.48 (-0.04)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.43 (-0.07), PSTI: 1.48 (-0.04), ATHX: 2.38 (+0.03), CLBS: 0.53 (unch)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 7.07 (+0.16), PSTI: 1.48 (-0.04), CGEN: 6.43 (-0.19), CBLI: 2.61 (+0.01)
Pluristem (PSTI) Gets FDA Approval for Phase I PLX-R18 Trial
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 2:35PM CST
Pluristem Therapeutics (PSTI) announced that the FDA has cleared its IND application to begin a phase I trial on PLX-R18 cells for treating incomplete hematopoietic recovery following hematopoietic cell transplantation.
GILD: 84.45 (-1.32), PSTI: 1.48 (-0.04), AZN: 27.97 (-0.99), ANIK: 49.16 (+0.24)
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.48 (-0.04), GALT: 1.42 (-0.05), LLY: 73.95 (-0.48), BMY: 72.65 (-0.08), GLPG: 55.29 (-1.59), GILD: 84.45 (-1.32), IBIO: 0.61 (-0.02), TEVA: 53.01 (-0.30), FGEN: 17.59 (-0.80), CELGZ: 1.46 (-0.04)
MannKind Plunges on Termination of Afrezza Deal with Sanofi
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 1:45PM CST
Shares of MannKind Corporation (MNKD) plummeted 48.4% after the company announced the termination of its license and collaboration agreement with Sanofi (SNY) for Afrezza.
PSTI: 1.48 (-0.04), JUNO: 42.98 (-2.55), SNY: 39.41 (-1.45), MNKD: 1.01 (-0.02)
Pluristem's PLX-PAD Cells Get Orphan Drug Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jan 04, 8:30AM CST
Pluristem Therapeutics announced that the FDA has granted its placental-derived (PLX-PAD) cells Orphan Drug designation for the treatment of severe preeclampsia.
PSTI: 1.48 (-0.04), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), BXLT: 46.02 (-0.18)
